EUVIMEDEUVIMED entdecken
Validierungsstudie

Lung cancer in primary care: Development & validation of a prediction algorithm

Francesco Lapi, Ettore Marconi, Elisa Bianchini, Marco Gorini, Ryan Bate, Gerardo Medea, Iacopo Cricelli

Cancer Epidemiology · 2026-08 · 103 · 103104

DOI: 10.1016/j.canep.2026.103104 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Epidemiology, 2026-08. Verfasst von Francesco Lapi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomedics SRL, Florence, Italy. Electronic address: francesco.lapi@genomedics.it. Hauptthemen laut MEDLINE: Lung Neoplasms, Primary Health Care. Die Arbeit nennt 43 Literaturangaben. Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer (LC) is among the most common and life-threatening cancer worldwide. Early identification in primary care through robust predictive models can enhance early referral and improve outcomes. METHODS: This cohort study included 3,454,735 patients aged ≥ 30 years from an Italian federated network of general practitioners' (aggregated) data, spanning 2002-2021. We developed and validated a multivariable prediction algorithm for 5-year LC risk. Risk factors included demographics, lifestyle exposures, comorbidities, and symptoms. A Cox proportional hazard model was estimated and performance assessed using pseudo-R2, AUC, and calibration metrics. Model overfitting was assessed via bootstrap methodology. Risk thresholds were established with the goal of developing a decision support tool. RESULTS: Incidence rate of LC was 1.5/1000 person-years in development and validation cohorts. Multivariate analysis showed smoking (HR=14.75), COPD (HR=2.3), and advanced age (HR=1.29 for ≥80) as strong predictors as well as female sex (HR=2.46). Obesity (HR=0.74), diabetes (HR=0.91), and family history of LC (HR=0.48) showed inverse associations. The final model achieved pseudo-R2 of 0.609, AUC of 0.822, and calibration slope of 1.06 (p value 0.65). Bootstrap analysis confirmed model accuracy. The 5-year predicted risk of LC was 0.73%. Based on risk, low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsPrimary Health CareHumansPrediction AlgorithmsFemaleMaleMiddle AgedRisk FactorsAgedItalyAdultIncidenceAlgorithmsAged, 80 and overCohort Studies

Stichwörter der Autor:innen

AlgorithmLung cancerPredictionPrimary care

Autor:innen und Institutionen

  • Genomedics SRL, Florence, Italy. Electronic address: francesco.lapi@genomedics.it.
  • Genomedics SRL, Florence, Italy.
  • Innovation Unit & Business Excellence, AstraZeneca, Milan, Italy.
  • AstraZeneca, Field, UK.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Lapi, F., Marconi, E., Bianchini, E., Gorini, M., Bate, R., Medea, G., & Cricelli, I. (2026). Lung cancer in primary care: Development & validation of a prediction algorithm. Cancer Epidemiology, 103, 103104. https://doi.org/10.1016/j.canep.2026.103104

Vancouver

Lapi F, Marconi E, Bianchini E, Gorini M, Bate R, Medea G, et al. Lung cancer in primary care: Development & validation of a prediction algorithm. Cancer Epidemiology. 2026;103:103104. doi:10.1016/j.canep.2026.103104

BibTeX
@article{Lapi2026,
  author = {Lapi, Francesco and Marconi, Ettore and Bianchini, Elisa and Gorini, Marco and Bate, Ryan and Medea, Gerardo and Cricelli, Iacopo},
  title = {Lung cancer in primary care: Development & validation of a prediction algorithm},
  journal = {Cancer Epidemiology},
  year = {2026},
  volume = {103},
  pages = {103104},
  doi = {10.1016/j.canep.2026.103104}
}
Kostenlos starten →